association

Full identifier: http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association

Assigned to 1 class:

Minted in Nanopublication

 RAKPZmCZwm comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAKPZmCZwm...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co morbidities 1 1 relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies 1 2 relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 1 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of any patient 1 1 1 2 1 3 zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl 1 2 accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials zydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other co morbidities limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with cll zydelig is indicated for the treatment of patients with relapsed follicular b cell non hodgkin lymphoma fl who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 2 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with sll" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKPZmCZwm... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T14:32:34.213+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKPZmCZwm... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKPZmCZwm... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKPZmCZwm... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAKPZmCZwm...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAKPZmCZwm... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAKPZmCZwm...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 12 Jun 2021, 12:32:34 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co morbidities 1 1 relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies 1 2 relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 1 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of any patient 1 1 1 2 1 3 zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl 1 2 accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials zydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other co morbidities limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with cll zydelig is indicated for the treatment of patients with relapsed follicular b cell non hodgkin lymphoma fl who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 2 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with sll
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T12:32:34.213Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)